Dexamethasone/levofloxacin - NTC Pharma
Alternative Names: Levofloxacin/dexamethasoneLatest Information Update: 24 Apr 2022
At a glance
- Originator NTC
- Class Anti-inflammatories; Antibacterials; Antiemetics; Antineoplastics; Eye disorder therapies; Fluorinated steroids; Fluoroquinolones; Glucocorticoids; Non-opioid analgesics; Pregnadienetriols; Small molecules
- Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; Glucocorticoid receptor agonists; Immunosuppressants; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ocular inflammation; Ophthalmic infections
Most Recent Events
- 24 Apr 2022 No development reported - Phase-III for Ocular inflammation in Germany, Russia, Spain, Italy (Ophthalmic) (NTC Pharma website, April 2022)
- 24 Apr 2022 No development reported - Phase-III for Ophthalmic infections (Prevention) in Germany, Spain, Russia, Italy (Ophthalmic) (NTC Pharma website, April 2022)
- 17 Jun 2020 NTC Pharma grants license and distribution rights to Taro Pharmaceutical Industries for dexamethasone/levofloxacin in Israel